NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 4 July 2023

**Location:** 2 Redman Pl, London E20 1JQ and via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Dr Peter Baker-Gulliver Present for all items
4. Dr Patrick De Barr Present for all items
5. Dr Justin Daniels Present for all items
6. Ana Duarte Present for all items
7. Dr Steve Edwards Present for all items
8. Mohamad Farhat Present for all items
9. Hugo Pedder Present for all items
10. Dominic Pivonka Present for all items
11. Dr Mohit Sharma Items 1.1 to 5.1.3
12. Alan Thomas Present for all items
13. Jaqueline Tomlinson Present for all items
14. Min Ven Teo Items 1.1 to 4.1.3
15. Carole Pitkeathley Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Ian Watson, Associate Director Items 1.1 to 4.1.5

Janet Robertson, Associate Director Items 5.1 to 5.2.2

Jeremy Powell, Project Manager Items 1.1 to 4.1.5

Thomas Feist, Project Manager Items 5.1 to 5.2.2

Rumana Zaman, Administrator Items 1.1 to 4.1.5

Marcia Miller, Administrator Items 5.1 to 5.2.2

Yelan Guo, Heath Technology Assessment Adviser Items 1.1 to 4.1.5

Marcela Haasova, Heath Technology Assessment Analyst Items 1.1 to 4.1.5

Christian Griffiths, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Victoria Gillis-Elliott, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Carl Jackson, Assistant Project Manager Present for all items

Portia Dodds, Coordinator Present for all items

External assessment group representatives present

Nigel Fleeman, Liverpool Reviews and Implementation Group (LRIG)  Items 1.1 to 4.1.3

James Mahon, Liverpool Reviews and Implementation Group (LRIG) Items 1.1 to 4.1.3

Bram Ramaekers, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Steve Williamson, CDF representative, NHS England Present for all items

Dr Jennifer Glendenning, Consultant Clinical Oncologist, Clinical expert nominated by NCRI-ACP-RCP-RCR Items 1.1 to 4.1.3

Professor Andrew Tutt, Consultant Clinical Oncologist, Clinical expert nominated by Pfizer Items 1.1 to 4.1.3

Ms Helen Stewart, Patient Expert nominated by MET UP UK

 Items 1.1 to 4.1.3

Holly Heath, Patient Expert nominated by Breast Cancer Now

 Items 1.1 to 4.1.3

Paul Nathan, Consultant in Medical Oncology - clinical expert nominated by Melanoma Focus and Immunocore Items 5.1 to 5.1.3

Rumana Hussain, Consultant Ocular Oncologist – clinical expert nominated by Royal College of Pathologists Items 5.1 to 5.1.3

Jo Gumbs CEO – patient expert nominated by OcuMel Items 5.1 to 5.1.3

Observers present

Kusal Lokuge, Technical Analyst, NICE Items 1.1 to 4.1.3

Yuanyuan Zhang, Technical Analyst, NICE Items 1.1 to 4.3.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Radha Todd, welcomed members of the committee and other attendees to the meeting.
	2. The chair noted apologies from Andrew Champion, Becky Pennington, David Maudgil and Richard Ballerand.

### News and announcements

* 1. There are 2 public consultations now live on NICE website - deadline for responses COB Tuesday 25 July.

Part 1: [**Updates to NICE’s health technology processes manual**](https://www.nice.org.uk/guidance/indevelopment/gid-ngc10018/consultation/html-content)

Part 2: [**Revised approach to updating technology appraisal recommendations for COVID-19 medicines**](https://www.nice.org.uk/guidance/indevelopment/gid-ngc10019/consultation/html-content)

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 6 June 2023.

### Appraisal of [talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10366)

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10366v).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Justin Daniels (Clinical and Lay) and Mohit Sharma (Cost).

Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)

* + 1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10366v>

### Appraisal of [tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10428)

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Immunocore.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10428)
		3. The Chair, Radha Todd, led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Vice Chair, James Fotheringham.
	2. Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10428>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 1 August 2023 and will start promptly at 9:30.